AxeroVision, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
- Website
- https://www.axerovision.com/
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Phase 2
Completed
- Conditions
- Posterior BlepharitisMeibomian Gland Dysfunction
- Interventions
- Drug: AXR-270 Low DoseDrug: AXR-270 High DoseDrug: AXR-270 Vehicle
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- AxeroVision, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT04469998
- Locations
- 🇺🇸
AxeroVision, Inc., Carlsbad, California, United States
A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- AxeroVision, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03598699
- Locations
- 🇺🇸
Andover Eye Associates, Raynham, Massachusetts, United States
🇺🇸Total Eye Care, P.A., Memphis, Tennessee, United States
News
No news found